We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...
Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
By Rick Winterson Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge. It has now established its global headquarters on Fan Pier in South ...
Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...
CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results